A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Patients 13 Years or Older With Asthma
Teva Identifier
FSS-AS-40139
ClinicalTrials.gov Identifier
NCT04677959
Study Status
Completed
Trial Condition(s)
Asthma
Interventions
Drug: Fluticasone propionate/salmeterol (FS) | Drug: Albuterol | Drug: Standard of Care Asthma Medication | Drug: Standard of Care Rescue Medication
Study Description
The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) compared to the Standard of Care (SoC) group.
The secondary objective is to describe the asthma management actions by investigational center health care providers (iHCPs) for Female, Male participants in both groups, to evaluate short-acting beta2 agonist (SABA) usage and the number of SABA-free days in the DS group, to evaluate adherence patterns to maintenance treatment (FS eMDPI) in the DS group, to assess behavioral correlates of responsiveness to digital health technology among patients for Female, Male participants in both groups, to evaluate work productivity and activity impairment in asthma patients in both groups, to assess the usability and acceptability of the DS by patients in the DS group and the investigational center personnel, and to evaluate the safety of FS eMDPI and Albuterol eMDPI.
You are about to leave the Teva Pharmaceuticals global website
The website you are about to access may be governed by different regional policies, regulations or advertising codes. Please be sure to read the privacy policy and terms of use of the websites that you visit.
Teva Pharmaceuticals is not responsible for the accuracy or compliance with laws of information on any third party websites.